| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803085201052 | 308520105 | EGZYSTA CAPS 25MG/CAP BTx56 PVC/PVDC/ALU blisters | 3.37 | 3.53 | 4.87 |
| 05/2018 | 2803085203056 | 308520305 | EGZYSTA CAPS 75MG/CAP BTx56 PVC/PVDC/ALU blisters | 6.14 | 6.44 | 8.87 |
| 05/2018 | 2803085205050 | 308520505 | EGZYSTA CAPS 150MG/CAP BTx56 PVC/PVDC/ALU blisters | 8.20 | 8.60 | 11.85 |
| 05/2018 | 2803085208051 | 308520805 | EGZYSTA CAPS 300MG/CAP BTx56 PVC/PVDC/ALU blisters | 13.31 | 13.96 | 19.24 |
For management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin is unknown, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha2-delta subunit may be involved in pregabalinís antinociceptive and antiseizure effects in animal models. In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, possibly by modulation of calcium channel function.
Well absorbed after oral administration.
~6 hours
Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug.
* 0.5 L/kg
* Renal cl=67.0 – 80.9 mL/min [young healthy subjects]